News
Moderna, FDA and Covid
Digest more
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...
Pfizer and Moderna will now include more information on the risk of myocarditis on their COVID-19 vaccine labels.
Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed ...
Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback